SEC Probes Aveo Over Failed Renal Cancer Drug

Law360, New York (July 12, 2013, 7:42 PM EDT) -- Aveo Pharmaceuticals Inc. on Thursday said the U.S. Securities and Exchange Commission has launched a probe in connection with the drugmaker’s experimental kidney cancer drug, which in June was rejected by the U.S. Food and Drug Administration.

The Cambridge, Mass.-based company said it received a subpoena from the SEC on July 3 requesting documents and information concerning tivozanib, which the FDA in June declined to approve for the treatment of patients with advanced renal cell carcinoma.

Aveo said the SEC requested tivozanib-related communications with the FDA,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.